

1 **Article Title:** Lack of evidence for interactions between *APOE* and *Klotho* genotypes on
2 cognitive, dementia and brain imaging metrics in UK Biobank.

3 **Authors:** Rachana Tank MSc¹, Joey Ward BSc¹, Daniel J. Smith MD¹, Kristin E. Flegal²
4 PhD, Donald M. Lyall PhD¹.

5

6 ¹Institute of Health & Wellbeing, University of Glasgow, Scotland, UK.

7 ²Institute of Neurosciences and Psychology, University of Glasgow, Glasgow, Scotland, UK.

8

9 **Corresponding author**

10 Dr. Donald M. Lyall

11 1 Lilybank Gardens

12 Institute of Health and Wellbeing

13 University of Glasgow

14 G12 8RZ, Glasgow, UK.

15 Email: Donald.Lyall@Glasgow.ac.uk

16 Tel: +44 (0) 141 330 8547

17 Fax: +44 (0) 141 330 1874

18 **Search terms:** *Cognitive; dementia; brain; APOE; Klotho.*

19 **Acknowledgements:** This research has been conducted using the UK Biobank resource;
20 we are grateful to UK Biobank participants. Thanks to Dr. Breda Cullen for devising
21 exclusion criteria and Dr. Michael A. Belloy for helpful comments on an earlier draft. This
22 project was completed using UK Biobank application 17689 (PI: DML).

23 **Title character count:** 132

24 **Text word count:** 1295

25 **Abstract word count:** 245

26 **Supplementary Tables:** 1

27 **References:** 17

28 **Abstract**

29 Importance: Recent research has suggested that genetic variation in the *Klotho* (KL) locus
30 may modify the association between apolipoprotein e (*APOE*) e4 genotype and cognitive
31 impairment.

32 Objective: Large-scale testing for associations and interactions between *KL* and *APOE*
33 genotypes vs. risk of dementia (n=1,570 cases), cognitive abilities (n=174,513) and brain
34 structure (n = 13,158) in older (60+ years) participants.

35 Design, setting and participants: Cross-sectional and prospective data (UK Biobank).

36 Main outcomes and measures: *KL* status was indexed with heterozygosity of the rs9536314
37 polymorphism (vs. not), in unrelated people with vs. without *APOE* e4 genotype, using
38 regression and interaction tests. We assessed non-demented cognitive scores (processing
39 speed; reasoning; memory; executive function), multiple structural brain imaging, and clinical
40 dementia outcomes. All tests were corrected for age, sex, assessment centre, eight principal
41 components for population stratification, genotypic array, smoking history, deprivation, and
42 self-reported medication history.

43 Results: *APOE* e4 presence (vs. not) was associated with increased risk of dementia, worse
44 cognitive abilities and brain structure differences. *KL* heterozygosity was associated with
45 less frontal lobe grey matter. There were no significant *APOE/KL* interactions for cognitive,
46 dementia or brain imaging measures (all $P>0.05$).

47 Conclusions and relevance: We found no evidence of *APOE/KL* interactions on cognitive,
48 dementia or brain imaging outcomes. This could be due to some degree of cognitive test
49 imprecision, generally preserved participant health potentially due to relatively young age,
50 type-1 error in prior studies, or indicative of a significant age-dependent *KL* effect only in the
51 context of marked AD pathology.

52

53 **Key points**

- 54 • **Question:** *Klotho* genotype has been previously shown to ‘offset’ a substantial amount of
55 the *APOE* e4/cognitive impairment association. Is this modification effect apparent in
56 large-scale independent data, in terms of non-demented cognitive abilities, brain
57 structure and dementia prevalence?
- 58 • **Findings:** In aged 60 years and above participants from UK Biobank, we found
59 significant associations of *APOE* and *Klotho* genotypes on cognitive, structural brain and
60 dementia outcomes, but no significant interactions.
- 61 • **Meaning:** This could reflect somewhat healthy participants, prior type 1 error or
62 cognitive/dementia ascertainment imprecision, and/or that *Klotho* genotypic effects are
63 age and neuropathology dependent.

64 **Introduction**

65 Preserving cognitive abilities such as memory is a common concern into older age, and in
66 the absence of reliable treatments, the public health priority is prevention and delay of
67 cognitive impairment¹, including understanding effect modifiers. *APOE* e4 is a known risk
68 factor for AD and cognitive decline¹. Genetic variation in the *KL* locus has been associated
69 with ageing-related phenotypes including insulin resistance and brain function². A recent
70 study of AD cohorts, longitudinal conversion and amyloid-beta samples showed a
71 statistically significant ‘modification’ effect where the deleterious effects conferred by *APOE*
72 e4 were offset by heterozygosity based on two *KL* polymorphisms in strong linkage
73 disequilibrium: F352V (rs9536314) and C370S (rs9527025), possibly due to correlations with
74 increased serum Klotho³. UK Biobank is a relatively large general population cohort⁴ where
75 we have previously shown deleterious effects of *APOE* e4 on cognitive⁵, structural brain
76 imaging⁶ and AD/dementia phenotypes⁷. This brief report tested the hypothesis that based
77 on recent research, genetic *KL* variation would interact with *APOE* e4 genotype in relevant
78 cognitive, brain and dementia phenotypes.

79

80 **Methodology**

81 Study design and participants

82 UK Biobank is a prospective cohort study including 502,628 participants who attended one
83 of 22 baseline assessment centres from 2006 to 2010, aged 40-70 years⁸. In 2014, MRI
84 scanning of a sub-group of 100,000 participants began, and this is ongoing. This analysis
85 was conducted under generic approval from the NHS National Research Ethics Service
86 (approval letter dated 17th June 2011, ref 11/NW/0382). Written informed consent was
87 obtained from all participants in the study.

88 Dementia outcomes

89 Dementia/AD outcomes were generated using self-report, hospital admission and death
90 record data, with data utilising International Classification of Diseases version 10 (ICD-10
91 codes). Individuals were designated as cases (“all-cause dementia” or “Alzheimer disease”)
92 if they had indicated either in self-report or hospital/death records – derived by UK
93 Biobank^{7,9}. Those coded as missing were designated as controls (i.e. did not self-report
94 dementia, and diagnoses not present in hospital/death records).

95

96 Imaging data

97 The release of brain MRI data as of July 2020 was used (i.e. approximately 40k). All imaging
98 data used here was processed and quality checked by UK Biobank¹⁰. We selected imaging
99 phenotypes *a priori* shown to be associated with worse cognitive ability and decline total
100 white and grey volumes adjusted for skull size (WM/GM respectively); log WM
101 hyperintensity volume (WMH); overall hippocampal volume; general factors of fractional
102 anisotropy (FA) and mean diffusivity (MD), and frontal lobe GM (gFrontal)¹¹ based on
103 principal components analysis (PCA). Total WM hyperintensity volumes were calculated
104 based on T1 and T2 fluid-attenuated inversion recovery (FLAIR), derived by UK Biobank.

105

106 Cognitive data

107 Five tests were completed at baseline (2006-2010), of which we examine three here which
108 have shown sufficient intra-participant reliabilities: Pairs-matching 6-pair (memory), verbal-
109 numeric reasoning and log reaction time (processing speed)¹². We also examined four
110 cognitive tests administered from 2014 onwards. These were: Trail making test a+b
111 (processing speed/executive function) and Digit symbol substitution (executive function)
112 assessed via online follow-up, plus Matrix pattern completion (nonverbal reasoning) and
113 Tower rearranging (executive function) at MRI¹¹.

114

115 Genetic data

116 UK Biobank genotyping was conducted by Affymetrix using a bespoke BiLEVE Axiom array
117 for ~50,000 participants and the remaining ~450,000 on the Affymetrix UK Biobank Axiom
118 array. All genetic data were quality controlled by UK Biobank as described by the protocol
119 paper⁴). *APOE* e4 'risk' genotype presence (vs. non-e4) was genotyped based on rs7412
120 and rs429358. KL was indexed using rs9536314 where G/T is considered protective (vs.
121 G/G; T/T) and synonymous with KL-VS diplotype heterozygosity¹³.

122

123 Covariates

124 Participants self-reported their smoking history: current, past or never, medication use for
125 dyslipidaemia, hormone replacement therapy, blood pressure, oral contraceptive or insulin.
126 We excluded participants for whom these data were missing (<5%). Townsend deprivation
127 indices were derived from postcode of residence.

128

129 **Statistical analysis**

130 PLINK v1.90 was used for genetic quality controlling and Stata V.14 was used for statistical
131 analyses. We removed participants who reported neurological conditions as described
132 previously¹². We statistically controlled for: age, sex, Townsend, ever-smoking, genotypic
133 array, baseline/MRI assessment centre, 8 principal components, array, and medication
134 (concurrent to the phenotype under study; dementia outcomes used baseline values). We
135 focussed on participants aged ≥60 years at baseline³. We excluded participants with non-
136 white British ancestry, self-report vs. genetic sex mismatch, putative sex chromosomal
137 aneuploidy, excess heterozygosity, and missingness rate >0.1. We accounted for
138 relatedness between participants by removing one random participant in cases where two
139 individuals were 1st cousins or closer. We have previously reported power calculations
140 indicative of >95% confidence to find 'true' effect sizes at Cohen's D = 0.1 (i.e. small) with
141 regard to *APOE* genotype and outcomes in UK Biobank⁶.

142 **Results**

143 Descriptives

144 After exclusions there were baseline N=174,513 (mean age 64.1, SD=2.85) participants;
145 imaging n=13,158 (72.24 years; SD 3.31). For rs9536314 there were 47,593 heterozygotes
146 (G/T; 27%), and N=46,270 (26.63%) possessed an *APOE* e4 allele. There were n=1,570
147 dementia cases (0.9%) of which n=634 were AD (0.4%).

148

149 Outcomes

150 Supplementary Table 1 shows associations between *APOE* e4 genotype and multiple worse
151 outcomes: dementia (odds ratio[OR]=3.27 for e4 vs. not), AD (OR=5.06), log Tower
152 rearranging score (beta = -0.07 SDs for e4 vs. not), Matrix Reasoning (-0.11 SDs), frontal
153 lobe GM (-0.05), hippocampal volume (-0.10), overall GM (-0.06), log TMT total time (0.037)
154 and Digit symbol (-0.075; lowest P-value = 0.038). KL heterozygosity (vs. not) was
155 associated with gFrontal only (-0.041 SDs; P=0.043). There were no statistically significant
156 *APOE/KL* interactions. As sensitivity analyses all models were re-run: unadjusted then
157 covariates added incrementally; excluding people with concurrent neurological conditions¹²;
158 and using the full sample (aged <60). These made no difference to the results.

159

160 **Discussion**

161 A recent study by Belloy et al.³ reported a protective modifying effect of KL heterozygosity
162 on *APOE* e4 genotype's conferred risk on cognitive impairment and dementia, in a collation
163 of longitudinal, AD and amyloid-beta cohorts totalling N=24,743. Using unrelated UK
164 Biobank data we tested whether a similar effect could be seen in multiple outcomes: AD/all-
165 cause dementia vs. not, and non-demented cognitive and structural brain MRI phenotypes
166 known to underlie cognitive decline. Participants were ≥60 years as per Belloy et al. We
167 identified individual *APOE* and KL genotype/outcome associations but no interactions,
168 against our hypothesis. There could be an underestimation of true effect due to cognitive test
169 imprecision¹² or generally preserved participant health¹¹. No interaction here vs. Belloy et al.

170 could reflect the use of different phenotypes: the original study investigated AD case vs.
171 control status, conversion to impairment and amyloid-beta while this study investigated AD
172 status and non-demented cognitive/brain structure values. UK Biobank derived dementia
173 status largely from ICD codes whereas Belloy et al. used clinical and/or pathological
174 ascertainment. This could suggest that the age-dependent changes in KL expression, and
175 interaction with *APOE* status, manifest only beyond at least moderate AD-related
176 neuropathology (e.g. amyloid or tau)¹⁴. The null AD case/control interaction could reflect that
177 UK Biobank is relatively healthy and well-educated. It is possible the UK Biobank
178 participants were not sufficiently old; analysis of longitudinal cognitive and brain imaging
179 data (in independent data) is indicative of more pronounced KL heterozygosity effects
180 particularly into later life¹⁵.

181

182 Limitations

183 This study did not explore an exhaustive list of structural imaging phenotypes. There is some
184 degree of healthy volunteer bias in UK Biobank participants, and probably more so in
185 participants who returned for imaging. Some imaging participants would have been unable to
186 complete scanning due to contraindications related to poorer health, e.g.
187 pacemakers/stents¹¹.

188

189 Summary

190 A recent relatively large-scale study including cohort, case/control longitudinal and amyloid-
191 beta data showed a significant interaction whereby KL genotype modified the well-known
192 *APOE* e4 and dementia association. Using independent cognitive, structural brain and
193 dementia data, we did not support these prior findings; this could reflect some degree of bias
194 or imprecision in UK Biobank participants or phenotypes, or that the interaction while ‘true’ is
195 contingent on AD-related neuropathology: future studies should investigate this further in
196 deeply-phenotyped cohorts.

197 **Funding**

198 RT is funded by a Baillie Gifford doctoral student fellowship. UK Biobank was established by
199 the Wellcome Trust medical charity, Medical Research Council, Department of Health,
200 Scottish Government and the Northwest Regional Development Agency. It has also had
201 funding from the Welsh Assembly Government and the British Heart Foundation. DJS is
202 supported by an MRC Pathfinder grant.

203

204 **Role of the funder/sponsor**

205 The funders had no role in study design, data collection or management, analyses or
206 interpretation of the data, nor preparation, review or approval of the manuscript.

207

208 **Conflict of interest disclosures**

209 None.

210

211 **Author contributions**

212 Concept and design: DML

213 Acquisition, analysis, or interpretation of data: DML, RT.

214 Drafting of the manuscript: DML, RT.

215 Critical revision of the manuscript for important intellectual content: All co-authors.

216 Statistical analysis: DML.

217 Obtained principal study funding: DML, KF.

218 **References**

- 219 1. Crenshaw DG, Gottschalk WK, Lutz MW, et al. Using Genetics to Enable Studies on
220 the Prevention of Alzheimer's Disease. *Clin Pharmacol Ther.* 2013;93(2):177-185.
221 doi:10.1038/clpt.2012.222
- 222 2. Vo HT, Laszczyk AM, King GD. Klotho, the Key to Healthy Brain Aging? *Brain Plast.*
223 Published online 2018. doi:10.3233/bpl-170057
- 224 3. Belloy ME, Napolioni V, Han SS, Le Guen Y, Greicius MD. Association of Klotho-VS
225 Heterozygosity with Risk of Alzheimer Disease in Individuals Who Carry APOE4.
226 *JAMA Neurol.* Published online 2020. doi:10.1001/jamaneurol.2020.0414
- 227 4. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep
228 phenotyping and genomic data. *Nature.* Published online 2018. doi:10.1038/s41586-
229 018-0579-z
- 230 5. Lyall DM, Celis-Morales C, Lyall LM, et al. Assessing for interaction between APOE
231 ϵ 4, sex, and lifestyle on cognitive abilities. *Neurology.* Published online 2019.
232 doi:10.1212/WNL.0000000000007551
- 233 6. Lyall DM, Cox SR, Lyall LM, et al. Association between APOE e4 and white matter
234 hyperintensity volume, but not total brain volume or white matter integrity. *Brain*
235 *Imaging Behav.* Published online 2019. doi:10.1007/s11682-019-00069-9
- 236 7. Ferguson AC, Tank R, Lyall LM, et al. Alzheimer's Disease Susceptibility Gene
237 Apolipoprotein E (APOE) and Blood Biomarkers in UK Biobank (N = 395,769). *J*
238 *Alzheimer's Dis.* 2020;76(4):1541-1551. doi:10.3233/jad-200338
- 239 8. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for
240 Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age.
241 *PLoS Med.* 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
- 242 9. Wilkinson T, Schnier C, Bush K, et al. Identifying dementia outcomes in UK Biobank:

- 243 a validation study of primary care, hospital admissions and mortality data. *Eur J*
244 *Epidemiol.* 2019;34(6):557-565. doi:10.1007/s10654-019-00499-1
- 245 10. Alfaro-Almagro F, Jenkinson M, Bangerter NK, et al. Image processing and Quality
246 Control for the first 10,000 brain imaging datasets from UK Biobank. *Neuroimage.*
247 Published online October 24, 2017. doi:10.1016/j.neuroimage.2017.10.034
- 248 11. Ferguson AC, Tank R, Lyall LM, et al. Association of systolic blood pressure and body
249 mass index with cognitive and structural brain phenotypes in UK Biobank. *J*
250 *Hypertens.* Published online June 9, 2020. doi: 10.1097/HJH.0000000000002579
- 251 12. Lyall DM, Cullen B, Allerhand M, et al. Cognitive test scores in UK biobank: Data
252 reduction in 480,416 participants and longitudinal stability in 20,346 participants.
253 *PLoS One.* 2016;11(4). doi:10.1371/journal.pone.0154222
- 254 13. Mengel-From J, Soerensen M, Nygaard M, McGue M, Christensen K, Christiansen L.
255 Genetic variants in KLOTHO associate with cognitive function in the oldest old group.
256 *Journals Gerontol - Ser A Biol Sci Med Sci.* Published online 2016.
257 doi:10.1093/gerona/glv163
- 258 14. Neitzel J, Franzmeier N, Rubinski A, et al. KL-VS heterozygosity is associated with
259 reduced tau accumulation and lower memory impairment in Alzheimer's disease KL-
260 VS heterozygosity attenuates downstream effects of amyloid on tau and cognition.
261 *medRxiv.* Published online July 31, 2020:2020.07.29.20164434.
262 doi:10.1101/2020.07.29.20164434
- 263 15. de Vries CF, Staff RT, Harris SE, et al. Klotho, APOE ϵ 4, cognitive ability, brain size,
264 atrophy, and survival: a study in the Aberdeen Birth Cohort of 1936. *Neurobiol Aging.*
265 Published online 2017. doi:10.1016/j.neurobiolaging.2017.02.019